MYOM2 and plasmacytoma: In our study, the second ASCT was performed to patients who had elevations in serum or urine M-protein levels, elevation in bone marrow atypical plasma cells ratio, the occurrence of new lytic bone lesions or plasmacytoma, and any other evidence of clinical progression or relapse.